Practical implication
Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.
The TGA has outlined an updated schedule of fees and charges for applications and maintenance of therapeutic goods, becoming effective from July 1, 2026. This adjustment impacts sponsors maintaining products on the Australian Register of Therapeutic Goods (ARTG) significantly, as it alters the financial obligations associated with regulatory activities, including those under pharmacovigilance monitoring and Risk Management Plan (RMP) duties.
What changed: The TGA's schedule of fees and charges for regulatory activities related to therapeutic goods will be adjusted, effective July 1, 2026.
Why it matters: The new fees will create financial implications for sponsors, particularly for those managing products subject to pharmacovigilance and RMP obligations. This can affect their budgeting and compliance strategies.
Practical implication: Sponsors must prepare for increased costs tied to the submission and maintenance of products on the ARTG which will impact their regulatory budget planning and compliance processes.
View original source
Published from the Firecrawl policy change extraction pipeline.
